Alkermes plc. (ALKS) Form 8-K — Jul 28, 2026
Alkermes reported second quarter 2026 total revenue of $496.0 million, a significant increase from $390.7 million in the prior year period, driven by strong sales of VIVITROL, LYBALVI, and the newly launched LUMRYZ. Adjusted EBITDA rose to $139.2 million, up from $126.5 million year-over-year, despite GAAP net income falling to $0.5 million due to acquisition-related costs and a $26.4 million fair value adjustment for an Avadel milestone. The company announced a leadership transition effective August 1, 2026, with Blair Jackson succeeding Richard Pops as Chief Executive Officer. Mr.
Key figures
- Eps
- 0
- Revenue
- 496
- Net Income
- 0.5
- Cash Position
- 691.6
- Adjusted EBITDA
- 139.2
- Cvr Milestone Expense
- 26.4
- Guidance GAAPNet Loss
- (95) – (115)
- Guidance Total Revenue
- 1,730 – 1,840
- Total Revenue Yo YGrowth
- 27%
Price after filing
Close on the filing date to close N calendar days later (from $52.97). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.